AR012148A1 - Anticuerpo fas antihumano-humanizado - Google Patents

Anticuerpo fas antihumano-humanizado

Info

Publication number
AR012148A1
AR012148A1 ARP980101321A ARP980101321A AR012148A1 AR 012148 A1 AR012148 A1 AR 012148A1 AR P980101321 A ARP980101321 A AR P980101321A AR P980101321 A ARP980101321 A AR P980101321A AR 012148 A1 AR012148 A1 AR 012148A1
Authority
AR
Argentina
Prior art keywords
humanized
human
antibodies
fas antibody
fas
Prior art date
Application number
ARP980101321A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of AR012148A1 publication Critical patent/AR012148A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invencion provee anticuerpos para Fas antihumanos, humanizados, capaces de inducir la apoptosis en células que expresan Fas y que son utiles en eltratamiento de enfermedades autoinmunolngicas y de artritis reumatoide cronica; además la invencionprovee ADN que codifica las regiones variables de la cadenaH y de la cadena L de dichos anticuerpos, y métodos para humanizar anticuerpos.
ARP980101321A 1997-03-21 1998-03-23 Anticuerpo fas antihumano-humanizado AR012148A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6793897 1997-03-21

Publications (1)

Publication Number Publication Date
AR012148A1 true AR012148A1 (es) 2000-09-27

Family

ID=13359383

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101321A AR012148A1 (es) 1997-03-21 1998-03-23 Anticuerpo fas antihumano-humanizado

Country Status (15)

Country Link
EP (1) EP0866131A3 (es)
KR (1) KR19980080514A (es)
AR (1) AR012148A1 (es)
AU (1) AU736287B2 (es)
BR (1) BR9800937A (es)
CA (1) CA2232828A1 (es)
CZ (1) CZ85898A3 (es)
HU (1) HUP9800613A3 (es)
ID (1) ID20065A (es)
IL (1) IL123756A0 (es)
NO (1) NO981272L (es)
NZ (1) NZ330004A (es)
PL (1) PL325457A1 (es)
TR (1) TR199800517A3 (es)
ZA (1) ZA982371B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
ATE391136T1 (de) 1998-06-18 2008-04-15 Imed Ab Fas peptide und antikörper zur modulierung von apoptosis
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
EP1143994B1 (en) * 1999-01-11 2003-07-02 Leadd B.V. Use of apoptosis inducing agents in the preparation of a medicament for the treatment of (auto)immune diseases
AU2004233486B2 (en) * 1999-01-11 2007-09-13 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
CN1191861C (zh) 1999-05-24 2005-03-09 三共株式会社 含有抗Fas抗体的药物组合物
US20040001828A1 (en) * 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
EP1506237A1 (en) * 2002-05-17 2005-02-16 Fusion Antibodies Limited Treatment of cancer by the use of anti fas antibody
GB0306618D0 (en) * 2003-03-22 2003-04-30 Univ Newcastle Antibody
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
EP3374399A1 (en) 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
NZ275711A (en) * 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
NO971448L (no) * 1996-04-01 1997-10-02 Sankyo Co Rekombinante anti-Fas-antistoffer og DNA for disse

Also Published As

Publication number Publication date
KR19980080514A (ko) 1998-11-25
TR199800517A2 (xx) 1998-10-21
AU5937598A (en) 1998-10-15
CZ85898A3 (cs) 1998-10-14
HUP9800613A3 (en) 2001-04-28
NZ330004A (en) 1998-10-28
PL325457A1 (en) 1998-09-28
EP0866131A3 (en) 1999-12-15
IL123756A0 (en) 1998-10-30
NO981272D0 (no) 1998-03-20
AU736287B2 (en) 2001-07-26
CA2232828A1 (en) 1998-09-21
ID20065A (id) 1998-09-24
NO981272L (no) 1998-09-22
EP0866131A2 (en) 1998-09-23
ZA982371B (en) 1998-09-28
BR9800937A (pt) 2000-01-11
TR199800517A3 (tr) 1998-10-21
HUP9800613A2 (hu) 1999-02-01
HU9800613D0 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
AR012148A1 (es) Anticuerpo fas antihumano-humanizado
EP0974600A3 (en) Anti-interleukin-18 antibody
LU93274I2 (fr) Elotuzumab
DE60333732D1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
AR028927A1 (es) Anticuerpo monoclonal humano contra la molecula co-estimuladora ailim transductora de senales y uso farmaceutico del mismo
EP0765172A4 (en) FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
EP1461081A4 (en) ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
DE69942671D1 (de) Humanisierte antikoerper gegen gamma-interferon
WO2004046306A3 (en) Fully human antibody fab fragments with human interferon-gamma neutralizing activity
AU8727291A (en) Bispecific antibodies, method of production, and uses thereof
PE20050376A1 (es) Anticuerpos dirigidos a m-csf
MXPA04003291A (es) Uso de anticuerpos biespecificos para ragular respuestas inmunes.
CR6538A (es) Anticuerpos de humano, anti-avb3 recombinantes, acidos nucleicos que codifican a los mismos y metodo de uso
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
WO2001090192A3 (en) Bispecific immunoglobulin-like antigen binding proteins and method of production
HK1070907A1 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
EA200000216A1 (ru) Белки, связывающие интерлейкин-18, их получение и применение
PE20061395A1 (es) Anticuerpos contra miostatina
MY154009A (en) Anti-alpha v beta 6 antibodies
MX9704897A (es) Secuencias del anticuerpo anti-idiotipo monoclonal recombinante 3h1 relacionadas con el antigeno carcinoembrionico humano.
WO2003073982A3 (en) Anti-interleukin-1 beta analogs
AR036189A1 (es) Anticuerpos de interleuquina-1beta
ES2165506T3 (es) Antagonistas del il-8 para el tratamiento del asma.

Legal Events

Date Code Title Description
FB Suspension of granting procedure